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ABSTRACT
RBFOX1 and RBFOX2 are alternative splicing factors that are predominantly expressed in the brain and skeletal muscle. They
specifically bind the RNA element UGCAUG, and regulate alternative splicing positively or negatively in a position-dependent
manner. The molecular basis for the position dependence of these and other splicing factors on alternative splicing of their
targets is not known. We explored the mechanisms of RBFOX splicing activation and repression using an MS2-tethering assay.
We found that the Ala/Tyr/Gly-rich C-terminal domain is sufficient for exon activation when tethered to the downstream intron,
whereas both the C-terminal domain and the central RRM are required for exon repression when tethered to the upstream
intron. Using immunoprecipitation and mass spectrometry, we identified hnRNP H1, RALY, and TFG as proteins that specifically
interact with the C-terminal domain of RBFOX1 and RBFOX2. RNA interference experiments showed that hnRNP H1 and TFG
modulate the splicing activity of RBFOX1/2, whereas RALY had no effect. However, TFG is localized in the cytoplasm, and
likely modulates alternative splicing indirectly.
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INTRODUCTION
The RBFOX family splicing factors play important roles in
tissue-specific alternative splicing regulation. There are three
paralogs in mammals: RBFOX1—formerly known as A2BP1
(Ataxin-2 Binding Protein 1) or Fox-1—is specifically
expressed in brain, skeletal muscle, and heart (Jin et al.
2003; Underwood et al. 2005); RBFOX2—formerly known
as RBM9 (RNA-binding motif protein 9)—is more ubiq-
uitously expressed (Underwood et al. 2005); RBFOX3 is less
well studied, and was recently discovered to be the same as
NeuN (neuronal nuclei), a marker of post-mitotic neuronal
cells (Kim et al. 2009).
RBFOX proteins are characterized by a very highly
conserved RNA-Recognition Motif (RRM) that is nearly
invariant in human, mouse, zebrafish, fruitfly, and nematode
(Kuroyanagi 2009). The central RRM is flanked by less-
conserved N- and C-terminal domains unique to RBFOX
proteins. Unlike many other splicing factors, which tend to
have very degenerate binding sites, the RBFOX family of
proteins specifically binds to a (U)GCAUG element. Both
RBFOX1 and RBFOX2 genes express multiple isoforms
via alternative promoters and alternative cassette exons
(Nakahata and Kawamoto 2005; Underwood et al. 2005).
Both N- and C-terminal domains of the protein isoforms
are highly diversified, and some isoforms lack the second
half of the RRM. Therefore, some of these isoforms are
expected to have different activities or to lack alternative
splicing functions (Nakahata and Kawamoto 2005). Alter-
native splicing of RBFOX1 is regulated during neuronal
depolarization, allowing it to modulate the activity of its
target genes (Lee et al. 2009).
RBFOX-family proteins regulate alternative splicing pos-
itively or negatively in a position-dependent manner. They
usually promote exon inclusion when binding to the intron
downstream from an alternative cassette exon, and exon
skipping when binding to the upstream intron (Jin et al.
2003; Underwood et al. 2005; Ponthier et al. 2006; Zhou
et al. 2007; Zhang et al. 2008; Tang et al. 2009; Yeo et al.
2009). Several target genes have been extensively studied by
use of reporter minigenes such as mitochondrial ATP synthase
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g-subunit (F1g) (Jin et al. 2003), calcitonin/calcitonin-
gene-related peptide (CGRP) (Zhou et al. 2007), CaV1.2
L-Type calcium channel (Tang et al. 2009), fibronectin
(Jin et al. 2003), non-muscle myosin II heavy chain-B
(NMHC-B) (Nakahata and Kawamoto 2005), epithelial
cell-specific fibroblast growth factor receptor 2 (FGFR2)
(Baraniak et al. 2006), and RBFOX1 and RBFOX2 them-
selves (Damianov and Black 2010). Global analysis was
utilized more recently to evaluate the splicing regulatory
networks of the RBFOX family of proteins. A combination
of microarray, CLIP-seq, high-throughput RT–PCR, and
computational analyses by different laboratories resulted in
the identification of many endogenous target genes, and
confirmed the so-called ‘‘RNA map,’’ meaning that the
splicing outcome (activation or repression) depends in
a predictable manner on the location of the UGCAUG el-
ement (Zhang et al. 2008; Venables et al. 2009; Yeo et al.
2009). Certain other splicing factors, such as Nova and PTB,
also have a similar map with position-dependent activities
(Ule et al. 2006; Llorian et al. 2010). The fact that different
splicing factors with completely distinct binding sites have
RNA maps with similar features suggests a convergence in
the underlying molecular mechanisms of splicing regulation.
Despite the recent progress in the identification of endog-
enous targets, little is known about the molecular mechanisms
by which RBFOX proteins—or other splicing factors—regu-
late alternative splicing positively or negatively in a context-
dependent manner. Most studies to date have focused on the
repressive effect. Using a calcitonin/CGRPminigene as amodel,
Zhou and colleagues showed that RBFOX1/2 prevent SF1 from
binding to the branchpoint sequence in intron 3, and repress
the formation of the spliceosomal E9 complex; the proteins also
interfere with binding of Tra2b and SRSF6 (formerly SRp55)
to ESEs (Exonic Splicing Enhancers) via a UGCAUG binding
site in exon 4, and block the formation of the spliceosomal
E complex (Zhou and Lou 2008). Fukumura et al. (2009)
analyzed exon 9 of F1g as a model system, and found that
RBFOX1 represses this exon by inhibiting splicing of intron
9, which is U1-snRNP independent and U2-snRNP de-
pendent. RBFOX2 interacts with hnRNP H1 and cooper-
ates with it and with hnRNP F to repress exon IIIc of an
FGFR2 minigene by antagonizing the binding of SRSF1
(formerly SF2/ASF) (Mauger et al. 2008). The C-terminal
domain of RBFOX1 is critical for exon repression in an F1g
minigene (Fukumura et al. 2007). However, the potential
involvement of this domain in alternative exon activation,
or in repression of alternative exons flanked by U1-dependent
introns, has not been determined. The only study to date that
provided a mechanistic clue about splicing activation by Fox-
1/2 reported an interaction in a yeast two-hybrid assay be-
tween RBFOX1 and the U1-snRNP-specific U1-C polypeptide
(Ohkura et al. 2005).
Here we have started to systematically explore the mech-
anism of RBFOX1/2 regulation of alternative splicing. We
used an MS2-tethering assay to evaluate the requirement of
RBFOX1 domains in both exon activation and repression.
We found that the C-terminal portion is the only fragment
that is critical for cassette-exon activation when tethered to
the downstream intron. In contrast, both the RRM and the
C-terminal domain are required for exon repression when
tethered to the upstream intron. We also used coimmuno-
precipitation combined with mass spectrometry to identify
proteins that interact with the RBFOX1/2 C-terminal domain,
and evaluated their roles in RBFOX1/2 activity.
RESULTS
The C-terminal domain of RBFOX1 is sufficient
for exon activation when tethered
to the downstream intron
To elucidate the mechanisms of exon activation and re-
pression by RBFOX1, we first used an MS2 tethering assay to
determine whether the RRM and the flanking domains can
be separated. We replaced the RRM with the bacteriophage
MS2 coat protein, which specifically binds to a 21-nt RNA
stem–loop (Carey et al. 1983). We inserted this RNA element
in the intron downstream from exon 7 in a human SMN2
minigene (Fig. 1A; Hua et al. 2008). This minigene lacks
natural RBFOX1 binding motifs. The alternative exon 7 was
predominantly skipped when transiently cotranfected with
MS2 protein or RBFOX1 alone into HeLa cells (Fig. 1B,
lanes 1, 7). However, the MS2-Fox1(N,C) construct, in
which the RBFOX1 RRM was replaced by MS2 coat protein,
strongly induced exon 7 inclusion (Fig. 1B, lane 2). This
result shows that RBFOX1 can enhance exon inclusion when
tethered to the downstream intron, and that the RRM and
the flanking domains can be separated. We next asked which
domains are required for this effect. We only kept either the
N- or C-terminal domain fused with MS2 coat protein, and
cotransfected them with the SMN2 minigene. The C-terminal
domain but not the N-terminal domain was sufficient to
induce exon 7 inclusion (Fig. 1B, lanes 3, 4). We further
subdivided the C-terminal domain into two similarly sized
fragments. The C-terminal fragment, MS2-Fox1Cb, was fully
functional in exon activation. The fragment proximal to the
RRM, MS2-Fox1Ca, was less active, promoting exon inclusion
to a lesser extent (Fig. 1B, lanes 5, 6). However, Western
blotting showed that the expression level of MS2-Fox1Ca was
lower than that of the other mutants (Fig. 1C). Therefore, its
weaker activity in exon activation may simply reflect lower
protein expression.
Fox1N and Fox1Ca mutant proteins are mislocalized,
but restoring nuclear localization is not sufficient
to rescue their activity
We used indirect immunofluorescence against the Flag tag
to examine the localization of the different transiently
expressed constructs. MS2 protein gave a diffuse pattern in
RBFOX1/2 activation and repression mechanisms
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both nucleus and cytoplasm, whereas MS2-Fox1(N,C) local-
ized in the nucleus, as did the wild-type Fox-1 protein (Fig.
2A). As expected, the two mutant proteins that were active in
promoting exon 7 inclusion, MS2-Fox1C and MS2-Fox1Cb,
also localized in the nucleus. However, both MS2-Fox1N and
MS2-Fox1Ca, which completely or partially lost the splicing
activation potential, distributed in both the nucleus and the
cytoplasm (Fig. 2A). This result is consistent with previous
reports that the C-terminal region is critical for nuclear
localization (Nakahata and Kawamoto 2005; Lee et al.
2009).
To determine whether the lack of splicing activity is caused
by mislocalization, we forced MS2, MS2-Fox1N, and MS2-
Fox1Ca to localize in the nucleus by fusing an SV40 nuclear
localization signal (NLS) at the C terminus of the mutant
proteins. Indirect immunofluorescence confirmed their
nuclear localization (Fig. 2B). However, when cotransfected
with the SMN2 minigene, Fox1N-NLS still failed to promote
exon inclusion. Fox1Ca-NLS displayed slightly greater activ-
ity in exon activation, compared with the mutant without the
NLS, but it was still not fully functional (Fig. 2C). However,
this could again be due to its lower expression level; although
we transfected more plasmid to try to increase its expression,
this mutant protein failed to accumulate to the same level as
the other proteins, suggesting that it is less stable. We
conclude from these experiments that the N-terminal
domain of RBFOX1 is not functional in enhancing alterna-
tive exon inclusion.
Both the RRM and the C-terminal domain
are important for exon repression when tethered
to the upstream intron
As mentioned above, RBFOX1 usually promotes exon
skipping when binding to the upstream intron of alternative
cassette exons. We again used the MS2-tethering assay to
examine RBFOX1’s activity in exon repression. We modified
a b-globin PB1 minigene (Zhang et al. 2008) to address this
question. We mutated the three natural RBFOX1 motifs in
the upstream intron, as well as two motifs in the exon. We
then inserted an MS2 binding site in the intron upstream of
the alternative exon (Fig. 3A). The alternative exon was pre-
dominantly included when cotransfected with MS2 protein,
or vector, or RBFOX alone (Fig. 3B, lanes 1, 2, 8, 9). But
MS2 protein fused to the N terminus of RBFOX1 markedly
enhanced exon skipping (Fig. 3B, lane 3). Like all canonical
RRMs, the RBFOX1 RRM utilizes the b-sheet to bind
nucleic acids; two exposed phenylalanine residues in the
RNP (ribonucleoprotein) submotifs are essential for bind-
ing to RNA by intercalating with single-stranded bases
(Auweter et al. 2006). We mutated the two phenylalanines
to aspartic acids, which was reported to eliminate RNA
binding (Mayeda et al. 1994; Auweter et al. 2006), and
tested whether the resulting protein can still enhance exon
skipping when tethered via MS2. To our surprise, the 2
amino acid substitution completely abolished the exon
repression activity, even though the protein is still tethered
to the minigene transcript through MS2 (Fig. 3B, lane 4).
Similarly, the MS2-Fox1(N,C) mutant, which lacks the
entire RRM, failed to promote exon skipping (Fig. 3B, lane
5), although the same protein enhanced exon inclusion
when tethered to the downstream intron (see above). We
infer that the RRM, including specific RNA interacting
residues, is also involved in protein–protein interactions or
nonspecific RNA–protein interactions, which are essential
for exon repression, but not for exon activation.
FIGURE 1. The C-terminal domain of RBFOX1 is sufficient for exon
activation when tethered to the downstream intron. (A) Diagrams of the
modified SMN2 minigene and MS2-fused RBFOX1 constructs. An MS2
binding site was inserted in the intron downstream from exon 7. The
primers for RT–PCR are indicated by arrows below the exons. RBFOX1
has one RRM (gray) flanked by N-terminal (black square) and C-ter-
minal (white oval) domains. All of the protein constructs have a Flag
epitope tag at the N terminus, indicated by an open circle. The MS2
module also has a T7 tag at its N terminus, represented by a vertical bar.
(B) HeLa cells were cotransfected with the SMN2-MS2down reporter
minigene and different protein constructs. RNA and proteins were
extracted 48 h after transfection. Radioactive RT–PCR was performed to
measure the changes in the alternative splicing isoforms. (C) Western
blot analysis using Flag antibody was performed to show the expression
of the protein mutants. (*) Nonspecific band.
Sun et al.
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To test whether the N-terminal domain is necessary for
the repressive effect, we deleted it and kept the RRM and the
C-terminal domain after the MS2 tag. This mutant was fully
functional in inducing exon skipping, similar to the full-
length protein (Fig. 3B, lane 6). Therefore, the N-terminal
domain is not required for exon repression, while the RRM
is indispensable. When the RRM alone was fused to MS2, it
could not promote exon skipping (Fig. 3B, lane 7). We
conclude that both the RRM and C-terminal domain are
important for exon repression.
Coimmunoprecipitation and mass spectrometry
identify Fox-1C interacting proteins
To explore the mechanisms responsible for exon activation
by the C-terminal fragment of RBFOX1, we performed
coimmunoprecipitation (IP) and mass spectrometry to iden-
tify proteins that interact with MS2-Fox1C. We used MS2 as
a negative control. As both constructs have a T7 epitope tag
between the N-terminal Flag tag and MS2, we used T7
monoclonal antibody cross-linked to Protein G magnetic
beads for the IPs. The immunoprecipitated proteins were
eluted, separated by SDS-PAGE, and stained with Coomassie
Blue (Fig. 4A). We cut out eight prominent gel bands that
were only observed in the MS2-Fox1C sample and cor-
responding gel slices at the same positions of the MS2 sam-
ple. Proteins were in-gel digested with trypsin overnight at
room temperature. The tryptic peptides were extracted from
the gel and analyzed using LC-MS/MS. Multiple protein
candidates were identified, including several RNA-binding
proteins (Supplemental Table S1). We focused on three
candidate proteins: hnRNP H1, RALY, and TFG, which
had a high number of unique peptides
and high coverage and/or appeared most
likely to play roles in alternative splicing
based on their known properties.
To confirm theprotein interactions iden-
tified by mass spectrometry, we repeated
the co-IP using T7 antibody, followed by
Western blotting. To exclude the possi-
bility that the observed interactions are
actually mediated by binding to the same
RNA, rather than reflecting protein–
protein contacts, we also treated the cell
lysates with a ribonuclease/benzonase
cocktail before the IP. As both MS2 and
MS2-Fox1C have a Flag tag at the N ter-
minus, we used Flag antibody for West-
ern blotting to verify the IP efficiency.
TFG interacted strongly with Fox1C,
independently of RNA and/or DNA (Fig.
4B). RALY gave a stronger signal when the
lysate was pretreated with nuclease, in
total, post-IP and IP samples. We have
observed this with other RNA-binding
proteins, and hypothesize that these proteins are probably
associated with large RNP complexes, forming aggregates that
precipitate with cell debris or are otherwise poorly accessible to
the antibodies; nuclease treatment presumably increases the
solubility and accessibility of the proteins. Irrespective of
nuclease treatment, all three proteins—hnRNP H1, RALY, and
TFG—interacted specifically with Fox1C (Fig. 4B; Supplemen-
tal Table S1). All three proteins also interacted with full-length
RBFOX1, as seen by mass spectrometry analysis, confirming
the interaction specificity.
We carried out similar IP-Western experiments with
RBFOX2’s C-terminal domain, to investigate whether these
two paralogs have similar interacting partners. It was already
reported that RBFOX2 interacts with hnRNP H1 (Mauger
et al. 2008). Our data confirm the previous study, and further
show that RALY and TFG interact with the RBFOX2
C-terminal domain (Fig. 4C). These results indicate that
RBFOX1 and RBFOX2 have similar interacting partners,
consistent with their similar functions in alternative splicing
(Zhang et al. 2008).
Testing the involvement of hnRNP H/F, RALY, and
TFG in RBFOX2-mediated alternative splicing
We carried out a siRNA knockdown experiment to test the
functional significance of the observed protein–protein in-
teractions. As hnRNP H1 and hnRNP F are 78% identical
and appear to have redundant functions (Caputi and Zahler
2001), we knocked down both proteins simultaneously. We
transfected siRNAs against luciferase, hnRNP H/F, RALY, or
TFG into HeLa cells, and extracted both total RNA and protein
after 72 h. All of the proteins were efficiently knocked down
FIGURE 2. Subcellular localization of the RBFOX1 mutant proteins. (A) Indirect immuno-
fluorescence of HeLa cells transfected with the indicated constructs was performed using Flag
antibody. (B) Indirect immunofluorescence of HeLa cells transfected with RBFOX1 constructs
containing an SV40 NLS was carried out using Flag antibody. (C) HeLa cells were
cotransfected with the SMN2-MS2down reporter minigene and the indicated RBFOX1
constructs. RNA was extracted 48 h after transfection and analyzed as in Figure 1B.
RBFOX1/2 activation and repression mechanisms
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without significant changes in endogenous RBFOX2 levels (Fig.
5A). We tested selected RBFOX1/2 targets with cassette exons
that are either induced or repressed by RBFOX1/2 up-regulation,
as well as targets with mutually exclusive exons. These include
both new and previously reported targets (Zhang et al. 2008).
We also included HeLa cells with stable shRNA knockdown
of RBFOX2 as a positive control (Zhang et al. 2008).
Knockdown of hnRNP H1 and TFG resulted in similar
slight changes in alternative splicing of several RBFOX
endogenous targets, compared with RBFOX2 knockdown,
though not all of the targets were affected; this was the case for
all three types of alternative splicing patterns (Fig. 5B). This
result suggests that hnRNP H1 and TFG assist the function of
RBFOX in both exon activation and exon repression, through
their interaction with the C-terminal domain. In contrast,
knockdown of RALY had no effect on alternative splicing of
any of the RBFOX endogenous targets tested (Fig. 5B).
TFG is involved in alternative splicing regulation
of RBFOX targets
TFG (TRK-fused gene) is a chromosomal translocation partner
of NTRK1 (a nerve-growth-factor receptor gene) giving rise to
the TRK-T3 oncogene, which is associated with thyroid pa-
pillary carcinoma (Greco et al. 1995). TFG is part of signal-
transduction pathways, and interacts with the SH2 domain of
SHP-1, a protein–tyrosine phosphatase, whose activity it modu-
lates (Roccato et al. 2005). It also interacts with TANK and
NEMO, two proteins involved in the NF-kB pathway (Miranda
et al. 2006). To our knowledge, there was no evidence that TFG
can bind RNA or regulate RNA metabolism.
To investigate possible mechanisms through which TFG
regulates alternative splicing induced by RBFOX, we first
determined the subcellular localization of the protein. Previous
reports focused on TRK-T3, which comprises only an N-ter-
minal fragment of TFG, so the localization of full-length TFG
was not known. We prepared nuclear and cytoplasmic fractions
of HeLa cells, and analyzed them by Western blotting. We
probed for Caspase-3 as a cytoplasmic marker. Surprisingly,
TFG was mainly localized in the cytoplasm, with only a very
weak signal in the nucleus (Fig. 6A). We also carried out
immunofluorescence with antibodies against TFG or the V5 tag
to examine the localization of both endogenous and transfected
V5-tagged TFG. We observed that TFG protein localized in the
cytoplasm, possibly in the endoplasmic reticulum (Fig. 6B,C).
We could not detect a signal in the nucleus. To test whether
TFG can shuttle between the nucleus and the cytoplasm, we
treated HeLa cells with leptomycin B, a nuclear-export in-
hibitor. However, this treatment did not cause the TFG protein
to accumulate in the nucleus (Fig. 6B,C). But as leptomycin B
specifically inhibits the nuclear export receptor CRM1 (Yoshida
and Horinouchi 1999), we cannot exclude the possibility that
TFG shuttles through other pathways. Thus, it is possible that
TFG transiently localizes in the nucleus, where it modulates
RBFOX activity; alternatively, RBFOX1/2 might shuttle
to the cytoplasm, where it would interact with TFG, and
this would somehow be important for its nuclear function
in alternative splicing.
DISCUSSION
We characterized the function of RBFOX1 using an MS2-
tethering assay. We found that the C-terminal domain—
especially the last 100 amino acids—is important for both
FIGURE 3. Both the RRM and the C-terminal domain are required
for exon repression when tethered to the upstream intron. (A)
Diagrams of the modified b-globin-PB1 minigene and MS2-fused
RBFOX1 constructs. Three natural RBFOX1/2 binding sites in the
upstream intron and one natural binding site in the alternative exon
were mutated, and an MS2-binding site was inserted in the upstream
intron. The primers for RT–PCR are indicated by arrows below the
exons. All of the protein mutants have a Flag epitope tag, which is
indicated by an open circle. The RRM with two Phe-to-Asp mutations
is designated RRMDD. (B) HeLa cells were cotransfected with the
b-globin-PB1-MS2up reporter minigene and different RBFOX1 con-
structs. RNA and protein were extracted 48 h after transfection.
Radioactive RT–PCR was performed to detect the changes of the
alternative splicing isoforms. (C) Western blot analysis using Flag
antibody was performed to show the expression of the protein
mutants.
Sun et al.
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RBFOX1 nuclear localization and exon inclusion activity. It
was recently reported that the C-terminal sequence comprises
a putative hPY-NLS, a nuclear localization signal recognized
by karyopherin b2 (Boillee et al. 2006; Kuroyanagi 2009).
This sequence is conserved in both RBFOX1 and RBFOX2,
from C. elegans to human, and it is also present in some other
splicing factors, such as hnRNP A1, hnRNP D, hnRNP F, etc.
This is consistent with our localization results. It has also been
noted that some RBFOX1 isoforms lack the second half of the
C-terminal domain because of frame-shifting, and therefore,
they are not functional in splicing regulation (Nakahata and
Kawamoto 2005; Lee et al. 2009).
The RBFOX1 C-terminal domain alone is sufficient to pro-
mote alternative exon inclusion when tethered to the down-
stream intron via MS2. This result suggests that like modular
transcription factors and some splicing factors, such as SR
proteins and hnRNP proteins, RBFOX1 also has modular
nucleic acid-binding and functional domains. However,
both the RRM and the C-terminal domain are required for
alternative exon repression when tethered to the upstream
intron. This observation implies that different mechanisms are
involved in RBFOX1 activation versus repression. It is possible
that the RRM is also involved in protein–protein interactions
(Ding et al. 1999), which could be critical for exon re-
pression, but not for exon activation. An alternative scenario
is that RBFOX1 also needs to interact with other RNA
sequences—for example, elsewhere on the pre-mRNA to
loop out the exon, or with an snRNA in the spliceosome—in
addition to the engineered MS2-binding site for its re-
pressive activity, especially considering that the amino acid
substitutions in the canonical RNA-binding surface of the
RRM completely abolished the repression activity.
There are precedents for different domains of a splicing
factor being required in the context of its different activities.
For example, all SR proteins have one or two RRMs, and one
RS domain that is involved primarily in protein–protein
interactions (Long and Caceres 2009; Zhong et al. 2009). SR
proteins function in two distinct aspects of splicing: on one
hand, they are required for constitutive splicing and spliceo-
some assembly; on the other hand, they also regulate alterna-
tive splicing, e.g., upon binding to exonic splicing-enhancer
elements (Long and Caceres 2009). The RS domain alone is
sufficient for enhancer-dependent splicing, but not for consti-
tutive splicing in MS2-tethering in vitro splicing assays; the
latter reaction requires a full-length SR protein (Graveley and
Maniatis 1998). But, under some conditions the RS domain is
dispensable for general splicing in vitro (Zhu and Krainer
2000; Shaw et al. 2007).
Using co-IP and mass spectrometry, we identified several
RBFOX1-interacting proteins. Previously, the only known
interacting protein of RBFOX1 was Ataxin-2 (Shibata et al.
2000), which is how RBFOX1 was first discovered. We did
not find this protein in our analysis, probably because of its
tissue-restricted expression. We selected three prominent
candidates for further analysis: hnRNP H1, RALY, and
TFG. IP-Western validation showed that both RBFOX1 and
RBFOX2’s C-terminal domains bind to all of the three pro-
teins specifically, both before and after nuclease treatment.
The C-terminal domains of the RBFOX1 and RBFOX2
isoforms we studied are 58% identical, rich in Ala, Tyr,
and Gly residues, and have an overall positive charge. This
is consistent with the two paralogs having similar interact-
ing partners and functions. Using functional assays in
combination with RNAi, we showed that hnRNP H1 and
TFG modulate the activity of RBFOX1/2 in alternative
splicing, both in activation and repression. In contrast,
RALY had no effect on any of the targets we tested.
FIGURE 4. The C-terminal domains of RBFOX1 and RBFOX 2 interact
specifically with hnRNP H1, RALY, and TFG. (A) HeLa cells were
transfected with MS2 or MS2-Fox1C. The proteins were immunoprecip-
itated from whole-cell lysates using Protein G Dynabeads coated with T7
monoclonal antibody. The immunoprecipitated proteins were separated
on a gradient SDS–polyacrylamide gel and stained with Coomassie Blue.
(B,C) IP using T7 antibody cross-linked to Protein G Dynabeads and
Western blotting with Flag, hnRNP H1, RALY, and TFG antibodies. IPs
were performed either with (+) or without () nuclease treatment.
Whole-cell lysates, post-IP lysates, and IPs were blotted with the indicated
antibodies. (B) HeLa cells transfected with MS2 or MS2-Fox1C. (C) HeLa
cells transfected with MS2 or MS2-Fox2C. (*) Nonspecific bands.
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hnRNP H1 belongs to the superfamily of heterogeneous
nuclear ribonucleoproteins (hnRNPs). It binds to intronic
oligo-(G) sequences and regulates alternative exons nega-
tively or positively, depending upon the context (Chen
et al. 1999; Chou et al. 1999; Jacquenet et al. 2001; Caputi
and Zahler 2002; Garneau et al. 2005; Crawford and Patton
2006). It was recently shown that hnRNP F and hnRNP H
form a complex with RBFOX2, and this interaction enhances
hnRNP H/F’s ability to antagonize SRSF1 binding to FGFR2
exon IIIc (Mauger et al. 2008). Our
experiments showed that RBFOX1 can
also interact with hnRNP H1, and that
hnRNPH1 enhances the activity of
RBFOX1/2 in both exon activation and
exon repression. Thus, our data confirm
and extend the previous study, and
suggest that RBFOX1/2 and hnRNP H1
modulate each other’s activities in alter-
native splicing regulation.
RALY was originally identified as an
autoantigen that cross-reacts with
EBNA-1 of the Epstein-Barr virus in
infectious mononucleosis (Rhodes et al.
1997). It too is a member of the hnRNP
superfamily, and is also known as
hnRNP C-like 2. It is associated with
the spliceosomal C complex (Jurica et al.
2002), and is therefore suspected to be
involved in pre-mRNA splicing. How-
ever, to date there is no direct functional
evidence of such involvement, and no
extensive characterization of this protein.
Our data showed that RALY specifically
binds to RBFOX1/2. However, the func-
tional significance of this interaction
remains unknown, as knockdown of this
protein did not affect alternative splicing
of RBFOX1/2 endogenous targets.
TFG is a signaling protein (Roccato
et al. 2005; Miranda et al. 2006). We
included it in our functional study be-
cause it strongly and specifically inter-
acted with the C-terminal domain of
RBFOX1 and RBFOX2. Knockdown of
TFG markedly affected alternative splic-
ing of several RBFOX1/2 endogenous
targets, suggesting that TFG is indeed
involved in modulating the activity of
RBFOX1/2 splicing factors. However,
these two proteins do not appear to
colocalize at steady state when analyzed
by immunofluorescence. It is possible that
they interact transiently while shuttling,
and that this interaction is important for
the nuclear activity of RBFOX. Alterna-
tively, TFG may modulate RBFOX1/2’s functions indirectly,
such as by controlling post-translational modifications
through signaling pathways. Our data indicate that TFG
and RBFOX1 are part of the same protein complex, at least
in vitro, and it is possible that they do not contact each
other directly, but that each can physically interact with
a common binding partner. More extensive studies will be
required to uncover the precise mechanisms underlying the
effect of TFG on splicing regulation by RBFOX proteins.
FIGURE 5. Knockdown of hnRNP H/F and TFG showed modest inhibition on alternative
splicing of RBFOX2 endogenous targets. HeLa cells were transfected with the indicated
siRNAs. After 72 h, total proteins and RNAs were extracted. HeLa cells with stable knockdown
of RBFOX2 using shRNA were analyzed in parallel as the positive control. (A) Western blotting
analysis using the indicated antibodies. (B) Radioactive RT–PCR of RBFOX1/2 endogenous
targets. The targets are classified into three groups: cassette exons induced by RBFOX1/2,
cassette exons repressed by RBFOX1/2, and mutually exclusive exons. A representative diagram
is shown for each category. The quantified exon-inclusion level is indicated below each panel.
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MATERIALS AND METHODS
Plasmids
We inserted the MS2-binding site (59-GCGTACACCATCAGGG
TACGC-39) into SMN2 (Hua et al. 2008) and b-globin PB1 (Zhang
et al. 2008) minigenes by site-directed mutagenesis (Supplemental
Methods). Three RBFOX binding sites in the upstream intron and
two in the exon were mutated in PB1 (Supplemental Methods). We
used cDNAs corresponding to the best-characterized variants, known
as RBFOX1 isoform 4 (397 amino acids) and RBFOX2 isoform 1
(380 amino acids); the accession numbers in NCBI are NM_018723.3
and NM_001031695.2, respectively. The sequences flanking the RRM
in pcDNA-Flag-Fox1 (Zhang et al. 2008) were mutated to introduce
NcoRI and BamHI sites, and then the RRM (aa 118–189) was
replaced by T7-tagged MS2 coding sequences. We subcloned
MS2-Fox1C (aa 190–397), MS2-Fox1N (aa 1–117), and MS2-
Fox1Ca (aa 190–297) into pcDNA-Flag via BamHI/BglII and XhoI
sites. We deleted the first 108 amino acids of the C-terminal
domain in MS2-Fox1C by site-directed mutagenesis to create
MS2-Fox1Cb (aa 298–397). We inserted a DNA fragment coding
for an SV40 NLS (59-CCTAAGAAGAAACGTAAGGTC-39) before
the stop codon by mutagenesis to construct MS2-NLS, MS2-
Fox1N-NLS, and MS2-Fox1Ca-NLS. We cleaved MS2-Fox1C with
BamHI and XhoI to release the C-terminal domain of Fox1, and
subcloned the full-length Fox-1 via BglII and XhoI sites to create
MS2-Fox1; or subcloned both the RRM and C-terminal domain
to construct MS2-Fox1DN; or subcloned the RRM only to
construct MS2-Fox1RRM; or subcloned the C-terminal domain of
RBFOX2 (aa 184–380) to create MS2-Fox2C. We mutated the two
phenylalanines (F158 and F160) to aspartic acids by site-directed
mutagenesis.
Cell culture and transfection
We cultured HeLa cells in DMEM supplemented with 10% (v/v)
FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin. We used
Fugene 6 (Roche) or Lipofectamine 2000 (Invitrogen) to transfect
plasmids, and Oligofectamine (Invitrogen) to transfect siRNAs.
For knockdown experiments, we transfected siRNAs 72 h prior to
sample collection. The siRNA sequences were as follows: hnRNP
H1 59-CAAACAACGUUGAAAUGGA-39; hnRNP F 59-CGACC
GAGAACGACAUUUA-39; RALY 59-UAACGUACCUGUCAAG
CUC-39; TFG: 59-GAGGAAAACUUCUGAGUAA-39; luciferase:
59-GCCAUUCUAUCCUCUAGAGGA-39). For the nuclear-export
inhibition experiment, cells were treated with 10 ng/mL Lepto-
mycin B (Calbiochem) for 12 h.
Cell fractionation
We lysed cells in gentle lysis buffer (10 mMHEPES at pH 7.4, 10 mM
NaCl, 3 mM MgCl2, 0.5% [v/v] NP-40). We pelleted the nuclei at
2300g for 5 min at 4°C, and transferred the supernatant (cytoplasm)
to another tube. We washed the nuclei once with the same buffer, and
repelleted them.
Western blotting
We harvested the cells and lysed them in Laemmli buffer. The
primary antibodies included b-catenin (Sigma), Flag tag (Sigma),
hnRNP H1 (Abcam), hnRNP F (Santa Cruz), RALY (Abcam), and
TFG (Abcam). The secondary antibodies were goat anti-mouse or
anti-rabbit IgG (H+L) HRP-conjugated (Pierce), or labeled with
IRDye 800CW (LI-COR). For detection, we used an ECL kit (Roche),
or an Odyssey Infrared Imaging System (LI-COR).
RNA isolation and RT–PCR
To isolate total RNA from cells, we used Trizol (Invitrogen) and
treatment with RQ1 DNase I (Promega). For first-strand cDNA
synthesis, we used random hexamers and ImProm-II reverse
transcriptase (Promega). For radioactive PCR, we used AmpliTaq
(Roche), added [g-32P]dCTP, and amplified for 23–26 cycles. We
separated the PCR products on 6% nondenaturing polyacrylamide
gels, and detected them with an Image Reader FLA-5100 (Fuji).
PCR primer sequences are shown in the Supplemental Methods.
Immunofluorescence
We fixed HeLa cells with 4% (v/v) paraformaldehyde in PBS for 30
min, 48 h after transfection. We permeabilized cells in 0.2% (v/v)
Triton X-100 for 5 min. We then incubated the cells with Flag
antibody (5 mg/mL; Sigma) for 1 h, washed with PBS, and then
incubated with Alexa Fluor 594 or 488-conjugated goat anti-rabbit
IgG antibody (1:1000; Invitrogen) for 1 h. We imaged the cells with
a fluorescence microscope (Axioskop, Carl Zeiss).
Immunoprecipitation
Dynabeads Protein G was washed twice with Citrate-Phosphate Buffer
(CPB; 25 mM citric acid, 50 mMNa2HPO4 at pH 5.0), and incubated
with T7-tag monoclonal antibody for 1 h at room temperature (2 mL
of culture supernatant/10 mL of beads). We washed the beads twice in
500 mL of CPB, and twice in 0.2 M triethanolamine (pH 8.2) (Sigma).
We then resuspended the beads in 1 mL of 20 mM dimethyl
FIGURE 6. TFG is localized in the cytoplasm. (A) Western blot
analysis of HeLa cell subcellular fractionations using TFG and caspase-
3 antibody. (T) Total; (N) nucleus; (C) cytoplasm. (B) Indirect
immunofluorescence of HeLa cells with or without Leptomycin B
treatment using TFG antibody. (C) Indirect immunofluorescence of
HeLa cells transfected with V5-TFG was performed using V5
antibody.
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pimelimidate (Sigma) in 0.2 M triethanolamine (pH 8.2), and
incubated at 20°C for 30 min with gentle mixing to cross-link the
antibody to the beads. To stop the reaction, we resuspended the
beads in 1 mL of 50 mM Tris-HCl (pH 7.5) and mixed for 15 min
at room temperature. Finally, we washed the beads three times in
PBS. We lysed four 15-cm plates of HeLa cells in 4 mL of lysis
buffer (0.3% [v/v] NP-40, 200 mM NaCl, 50 mM Tris at pH 7.4,
1 mM DTT, 0.1 mM EDTA, 0.1 mM EGTA, with freshly added
1 mM sodium vanadate, 50 mM sodium fluoride and protease-
inhibitor cocktail), and sheared the DNA by passing sequentially
through a syringe with 20, 22, and 26G needles, three times each.
We added nuclease cocktail (1 U/mL RNase cocktail [Ambion],
500 U/mL Benzonase [Novagen], and 2 mM MgCl2), and in-
cubated on ice for 30 min. We then spun the lysates at 13,000g for
20 min at 4°C. We passed the supernatant through a 0.45-mm
syringe filter (with HT Tuffryn membrane, Pall Corporation). We
then added 80 mL beads (1:1 suspension) to the cleared lysates and
incubated for 1 h at 4°C. After washing five times in lysis buffer,
we resuspended the beads in Laemmli buffer and loaded the
supernatant on an SDS–polyacrylamide gel.
Mass spectrometry
We ran the samples on a NuPAGE Novex Bis-tris Mini Gel
(Invitrogen) and stained with Gelcode Blue Stain Reagent
(Pierce). We cut out specific bands from the gel and washed in
50% (v/v) ethanol/5% (v/v) acetic acid prior to reduction with
DTT and alkylation with iodoacetamide. We in-gel digested the
proteins with sequencing-grade trypsin overnight at room tem-
perature. We extracted peptides from the gel and analyzed them
by LC-MS/MS. We used a Proxeon nano-flow HPLC pump. The
buffer solutions were 5% (v/v) acetonitrile/0.1% (v/v) formic acid
(buffer A), and 80% (v/v) acetonitrile/0.1% (v/v) formic acid
(buffer B). Samples were loaded with the autosampler onto a 180-
mm i.d. fused silica capillary precolumn containing 3 cm of 5-mm
Aqua C 18 material (Phenomenex). The precolumn was then
connected to an analytical column of a 100-mm i.d. capillary with
a 5-mm pulled tip and packed with 12–13 cm of 3-mm Aqua C 18
material. Peptides were separated using a linear gradient from 5%
(v/v) acetonitrile, increasing at 0.5% per min for 90 min. The flow
rate was set at 300 nL/min (splitless). Peptides eluted from the
microcapillary fritless column were directly electrosprayed into
a linear ion-trap (LTQ) mass spectrometer (Thermo Finnigan) with
the application of a distal 2.4 kV spray voltage. A cycle of one full-
scan mass spectrum (400–1700 m/z), followed by five data-de-
pendent MS/MS spectra at a 35% normalized collision energy, was
repeated continuously throughout the chromatographic separation.
Obtained spectra were processed with MASCOT Distiller (Ma-
trix Science) using the default parameters for ion-trap data analysis.
LTQ MSMS spectra were searched with MASCOT version 2.2.04
against the human IPI nonredundant database (version 3.35) for
tryptic peptides, allowing for one missed cleavage. The peptide mass
tolerance was set for 30 ppm, and the fragment ion tolerance was
set for 0.6 Da. The modifications included in the search were
carbamidomethylation of cysteines as a fixed modification, oxida-
tion of methionine as a variable modification, and deamidation of
asparagines and glutamines as additional variable modifications.
Peptide-spectrum matches were accepted for expectation value
<0.5, resulting in a false discovery rate <1% when compared with
decoy database hits.
SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.
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